Trial Profile

Phase I trial of EPZ 6438 in children with INI1-deficient solid tumours, including malignant rhabdoid tumours.

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 10 Aug 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tazemetostat (Primary)
Indications Rhabdoid tumour; Solid tumours
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Epizyme

Most Recent Events

04 Aug 2017 According to an Epizyme media release, the company initiated the dose-expansion portion of the study in Jul 2017.
09 Nov 2015 Interim results presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2015
26 Sep 2015 Planned number of patients changed from 40 to 51, as per Epizyme media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com